NCT05112848 - A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19) | Biotech Hunter

Enrollment

384

Participants

Timeline

Start Date

February 28, 2022

Primary Completion Date

May 23, 2022

Study Completion Date

November 30, 2022

Conditions

SARS-CoV-2 Infection

Interventions

BIOLOGICAL

NVX-CoV2373

"Alternating intramuscular (IM) (deltoid) injections of monovalent prototype vaccine premixed with Matrix-M™ adjuvant (0.5 mL) given either as~2 doses (one on Day 0 and one on Day 21 or Day 70) and an injection of placebo (0.5mL) on Day 21 or Day 70, or 3 doses (Day 0, Day 21, and Day 70)."

Trial Locations (7)

250

Madibeng Centre for Research, Brits

1055

MERC Research (Pty) Ltd - Middelburg, Middelburg

1862

Wits Vaccines & Infectious Diseases Analytics (VIDA) Research Unit, Diepkloof

2001

Wits RHI Shandukani Research Centre, Hillbrow

4091

KwaPhila Health Solutions (Enhancing Care), Westridge

9301

Josha Research, Bloemfontein

0087

The Aurum Institute Pretoria Clinical Research Services, Pretoria